Nathan Caffo
Corporate Officer/Principal chez CANDEL THERAPEUTICS, INC.
Profil
Nathan Caffo is a professional who has worked in the biotech industry.
He is currently the Chief Business Officer at Candel Therapeutics, Inc. He previously worked as the President & Chief Executive Officer at Presage Biosciences, Inc. from 2009 to 2018, and as the Chief Business Officer at ALX Oncology Holdings, Inc. from 2018 to 2020.
Mr. Caffo received his undergraduate degree from The Pennsylvania State University.
Postes actifs de Nathan Caffo
| Sociétés | Poste | Début |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2020 |
Anciens postes connus de Nathan Caffo
| Sociétés | Poste | Fin |
|---|---|---|
| ALX ONCOLOGY HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 |
Presage Biosciences, Inc.
 Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Chief Executive Officer | 17/07/2018 |
Formation de Nathan Caffo
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| ALX ONCOLOGY HOLDINGS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Presage Biosciences, Inc.
Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
